Business
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today voted in favor of the proposals required to complete the transactions announced in November, including the consummation of the PIPE financing and the related Daewoong note exchange - IRVINE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a
About this update from Aeon Biopharma, Inc.
[{"type":"image","alt":"AEON Biopharma Inc","displaySize":"","headline":null,"caption":"AEON Biopharma Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":132,"height":32,"url":"https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L69JurVw8dq7IznuR4WbIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5","width":132,"height":32}},"lazy":false},{"type":"text","content":"- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes -","length":162,"tagName":"p"},{"type":"text","content":"- Separately, AEON shareholders today voted in favor of the proposals required to complete the transactions announced in November, including the consummation of the PIPE financing and the related Daewoong note exchange -","length":220,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA), today reported on two separate positive events for the Company:","length":355,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"AEON confirmed that earlier today it held its scheduled BPD Type 2a meeting with FDA, in line with prior guidance. The Company looks forward to commenting on the meeting’s substance and outcome following receipt of the official meeting minutes from the U.S. Food and Drug Administration (“FDA”).","length":295,"tagName":"p"}]},{"val":[{"type":"text","content":"AEON also held today a special meeting at which shareholders voted to approve the completion of the transactions announced in November, including the remaining issuances related to the Company’s private investment in public equity (“PIPE”) financing and the related exchange of the Company’s convertible notes held by Daewoong Pharmaceutical Co., Ltd. (“Daewoong”). As previously disclosed, the Daewoong note exchange, which closed today following shareholder approval, will substantially reduce the Company’s outstanding debt and further simplif...